CAS No 222716-86-1 , Pegaptanib Sodium

Name: Pegaptanib Sodium
Synonyms: UNII-3HP012Q0FH;5'-Ester of (2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'-3')-dT with alpha,alpha'-(((1S)-1-((5-(phosphonooxy)pentyl)carbamoyl)pentane-1,5-diyl)bis(iminocarbonyl))bis(omega-methoxypoly(oxyethane-1,2-diyl)) octacosasodium salt. Molecular weight is approximately 50,000 daltons;Pegaptanib Sodium;Pegaptanib octasodium;NX 1838;EYE001;EYE 001;Macugen;RNA, ((2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'-3')-dT), 5'-ester withalpha,alpha'-(4,12-dioxo-6-(((5-(phosphonooxy)pentyl)amino)carbonyl)-3,13-dioxa-5,11-diaza-1,15-pentadecanediyl)bis(omega-methoxypoly(oxy-1,2-ethanediyl)), sodium salt;Pegaptanib sodium;
CAS Registry Number:222716-86-1
Molecular Weight: 535.5031
InChI: InChI=1S/C20H40N3O10P.Na/c1-29-13-15-31-19(25)22-11-7-5-9-17(23-20(26)32-16-14-30-2)18(24)21-10-6-4-8-12-33-34(3,27)28;/h17H,4-16H2,1-3H3,(H,21,24)(H,22,25)(H,23,26)(H,27,28);/t17-;/m0./s1
Molecular Formula: C₂₀H₄₀N₃NaO₁₀P
Molecular Structure:

Related products

1/1

References of Pegaptanib Sodium

Title: Pegaptanib Sodium
CAS Registry Number: 222716-86-1
Synonyms: PEG-t44-OMe
Manufacturers' Codes: EYE-001; NX-1838
Trademarks: Macugen (Eyetech)
Literature References: 2￠-Fluoropyrimidine RNA aptamer to human VEGF165; composed of 28-mer oligonucleotide conjugated to 40 kDa polyethylene glycol moiety. Prepn: N. Janjic et al., WO 9818480; eidem, US 6168778 (1998, 2001 both to NeXstar Pharm.); and binding affinity studies: J. Ruckman et al., J. Biol. Chem. 273, 20556 (1998). Inhibition of in vitro VEGF-mediated responses: C. Bell et al., In Vitro Cell. Dev. Biol. Animal 35, 533 (1999). HPLC determn in plasma: C. E. Tucker et al., J. Chromatogr. B 732, 203 (1999). Pharmacokinetics: D. W. Drolet et al., Pharm. Res. 17, 1503 (2000). Pharmacology and clinical safety study: Eyetech Study Group, Retina 22, 143 (2002). Clinical study in age-related macular degeneration: E. S. Gragoudas et al., N. Engl. J. Med. 351, 2805 (2004). Review of development and therapeutic potential: S. A. Vinores, Curr. Opin. Mol. Ther. 5, 673-679 (2003); of clinical experience and safety in macular degeneration: A. A. Moshfeghi, C. A. Puliafito, Expert Opin. Invest. Drugs 14, 671-682 (2005).
Therap-Cat: In treatment of age-related macular degeneration and diabetic macular edema.
Keywords: Macular Degeneration Treatment.